SLC16A1 and prostate cancer: Involvement of MCT2 in cancerogenesis was indicated for prostate cancer (Pértega-Gomes et al., 2015), colorectal cancer (Lee et al., 2012), and glioblastoma (Mathupala et al., 2004), while MCT1 is a known biomarker for carcinogenesis and its overexpression is associated with breast, bone, colon, renal, and bladder cancers (Park et al., 2018).